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Abstract
Aims Everolimus-eluting stents (EES) were superior to
sirolimus-eluting stents (SES) in a dedicated myocardial in-
farction trial, a finding that was not observed in trials with low
percentages of ST-elevation myocardial infarction (STEMI).
Therefore, this study sought to investigate the influence of
clinical presentation on outcome after EES and SES
implantation.
Methods A pooled population of 1602 randomised patients
was formed from XAMI (acute MI trial) and APPENDIX-
AMI (all-comer trial). Primary outcome was cardiac mortality,
MI and target vessel revascularisation at 2 years. Secondary
endpoints included definite/probable stent thrombosis (ST).
Adjustment was done using Cox regression.
Results In total, 902 EES and 700 SES patients were included,
of which 44% STEMI patients (EES 455; SES 257) and 56%
without STEMI (EES 447; SES 443). In the pooled popula-
tion, EES and SES showed similar outcomes during follow-
up. Moreover, no differences in the endpoints were observed
after stratification according to presentation. Although a trend
toward reduced early definite/probable ST was observed in
EES compared with SES in STEMI patients, long-term ST
rates were low and comparable.
Conclusions EES and SES showed a similar outcome during
2-year follow-up, regardless of clinical presentation. Long-
term safety was excellent for both devices, despite wide
inclusion criteria and a large sub-population of STEMI
patients.
Keywords Drug-eluting stents . Percutaneous coronary
intervention . Coronary artery disease
Introduction
Drug-eluting stents (DES) were designed to reduce the in-stent
neointimal hyperplasia that commonly occurred in bare-metal
stents (BMS). Indeed, first-generation DES (i.e. paclixatel-
eluting stents (PES) and sirolimus-eluting stents (SES)) re-
duced the need for revascularisation procedures compared with
BMS but were associated with higher rates of late stent throm-
bosis (ST), especially in complex patients such as those pre-
senting with myocardial infarction (MI) [1–3].
Delayed arterial healing and stent malapposition were found
to play a role in the higher ST rates after DES implantation in the
setting of MI [4, 5]. Second-generation DES were designed to
be safer and more effective through changes in stent design,
polymer and anti-restenotic drugs. So far, second-generation
everolimus-eluting stents (EES) have shown superior results to
PES in a wide range of indications [6]. Compared with SES,
EES have mostly shown comparable outcomes but improve-
ments in ST rates have been observed [7–10]. In contrast, one
dedicated trial of predominantly ST-segment elevation myocar-
dial infarction (STEMI) patients showed superiority of EES
over SES during short-term follow-up [11]. Long-term
randomised data are scarce, especially in setting of STEMI.
This study sought to investigate the influence of clinical
presentation on outcome of EES and SES during 2-year
follow-up.
M. A. Velders (*) :A. J. van Boven : J. Brouwer :C. J. de Vries :
M. Queré : S. H. Hofma
Department of Cardiology, Medical Center Leeuwarden, PO Box
888, 8901 BR Leeuwarden, the Netherlands
e-mail: m.a.velders@lumc.nl
P. C. Smits
Department of Cardiology, Maasstad Hospital, Rotterdam, the
Netherlands
A. W. J. van ’t Hof
Department of Cardiology, Isala Clinics, Zwolle, the Netherlands
Neth Heart J (2014) 22:167–173
DOI 10.1007/s12471-014-0525-0
Methods
Patient-level data from the randomised XAMI and
APPENDIX-AMI trials were pooled to form the patient pop-
ulation. The design and results of these trials have been
published previously [11, 12]. In short, XAMI (NTR1123,
http://www.trialregister.nl/trialreg/admin/ctview.asp?TC=
1123) was a multicentre, clinical non-inferiority trial
randomising 625 acute MI patients to EES (Xience V
[Abbott Vascular, Santa Clara, California]) or SES (Cypher
[Cordis, Bridgewater, New Jersey]) in a 2:1 ratio. To be
enrolled, patients had to have STEMI or non-STEMI with
an emergency indication for percutaneous coronary interven-
tion (PCI). Exclusion criteria were: chronic total occlusion as
target lesion; known allergy to sirolimus, everolimus, aspirin
or clopidogrel; inability to obtain informed consent; life ex-
pectancy <1 year; or stent size required to treat lesion >3.
5 mm.
APPENDIX-AMI (NTR3170, http://www.trialregister.nl/
trialreg/admin/rctview.asp?TC=3170) was a single-centre
open-label trial randomising 977 all-comer patients to EES
and SES (ratio 1:1). The trial included all patients eligible for
coronary revascularisation by PCI for any indication.
Exclusion criteria were: known allergy for everolimus or
sirolimus, aspirin or clopidogrel; inability or unwillingness
to give informed consent; and anatomy in which stent implan-
tation is deemed not technically possible.
Patients were pretreated with loading doses of aspirin and
clopidogrel, in addition to intravenous heparin bolus of
5000 IE in case of MI. Use of glycoprotein IIb/IIIa inhibitors,
thrombus aspiration and balloon pre-dilatation were left up to
the discretion of the operator. Aspirin was recommended for
life and clopidogrel for a minimum of 1 year. Protocol-defined
follow-up was performed after 30 days, 1 year and 2 years by
questionnaires and telephone contact. Follow-up was gathered
by research nurses in a blinded fashion. Event adjudication
was performed by a blinded clinical event committee in
XAMI. In APPENDIX-AMI, event adjudication was per-
formed between physicians on a consensus basis in an un-
blinded fashion. The study protocols were approved by the
local ethics committees of the participating centres and the
trials were conducted according to the principles of the
Declaration of Helsinki. All patients gave oral consent before
enrolment and written informed consent after procedure.
Definitions
The primary endpoint was a composite of cardiac death, MI
and target vessel revascularisation (TVR).MIwas defined as a
rise of creatine kinase (CK) more than three times the upper
Table 1 Baseline characteristics
STEMI Other indications
Variable EES (N=455) SES (N=257) p value EES (N=447) SES (N=443) p value
Age, years 61.8±11.4 62.4±11.5 0.501 65.2±11.3 65.1±11.1 0.868
Male 329 (72.3 %) 194 (75.5 %) 0.356 319 (71.4 %) 319 (72.0 %) 0.831
Diabetes mellitus 41 (9.1 %) 26 (10.2 %) 0.612 73 (16.9 %) 80 (18.6 %) 0.492
Hypertensiona 136 (30.1 %) 81 (31.8 %) 0.643 191(43.6 %) 223 (51.5 %) 0.020
Hypercholesterolaemiab 124 (27.8 %) 60 (23.8 %) 0.250 242 (57.5 %) 246 (57.9 %) 0.906
Current smoker 232 (51.3 %) 135 (53.1 %) 0.642 121 (27.6 %) 94 (21.9 %) 0.051
Prior myocardial infarction 32 (7.0 %) 19(7.4 %) 0.858 100 (22.6 %) 102 (23.2 %) 0.844
Prior PCI 19 (4.2 %) 9 (3.5 %) 0.653 81 (18.2 %) 105 (23.7 %) 0.046
Prior CABG 4 (0.9 %) 5 (1.9 %) 0.221 47 (10.5 %) 71 (16.0 %) 0.016
Prior renal insufficiency 8 (1.8 %) 6 (2.4 %) 0.596 49 (11.8 %) 43 (10.6 %) 0.598
Presenting diagnosis 0.072
- Stable angina 0 (0.0 %) 0 (0.0 %) – 251 (56.2 %) 275 (62.1 %)
- Unstable angina or non-STEMI 0 (0.0 %) 0 (0.0 %) – 196 (43.8 %) 168 (37.9 %)
- STEMI 455 (100 %) 257(100 %) – 0 (0.0 %) 0 (0.0 %) –
Symptoms to first medical contact (min) 90 (60–170) 100 (60–185) 0.419 – –
First medical contact to balloon inflation (min) 75 (60–100) 75 (60–100) 0.937 – –
Data are expressed as mean±SD, as number (percentage), or as median (interquartile range). CABG=coronary artery bypass grafting
a Blood pressure 140/90 mm Hg or previous pharmacological treatment
b Total cholesterol 190 mg/dl or previous pharmacological treatment
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limit of normal along with a rise in CK-MB with recurrent
symptoms and/or new electrocardiographic changes. In acute
coronary syndrome patients, re-infarction within 48 h after
index procedure was defined as a re-elevation of CK of >1.5
times the previous value with elevation of CK-MB, along with
recurrent symptoms and/or new electrocardiographic changes.
MI around coronary artery bypass grafting required a CK rise
of >5 times the upper limit of normal. TVRwas defined as any
repeat percutaneous or surgical intervention on any segment
of the target vessel. Other secondary endpoints included the
Table 2 Procedural characteristics
STEMI Other indications
Variable EES (N=455) SES (N=257) p value EES (N=447) SES (N=443) p value
Target coronary lesion 0.651 0.108
- Left main artery 0 (0.0 %) 1 (0.4 %) 26 (5.9 %) 15 (3.4 %)
- Left anterior descending artery 175 (38.5 %) 104 (40.5 %) 195 (44.0 %) 175 (39.8 %)
- Left circumflex artery 86 (18.9 %) 50 (19.5 %) 96 (21.7 %) 124 (28.2 %)
- Right coronary artery 192 (42.3 %) 101 (39.3 %) 124 (28.0 %) 124 (28.2 %)
- Bypass graft 1 (0.2 %) 1 (0.4 %) 2 (0.5 %) 2 (0.5 %)
Multivessel disease 206 (45.3 %) 130 (50.6 %) 0.173 249 (55.8 %) 252 (56.9 %) 0.751
Bifurcation intervention 55 (12.1 %) 37 (14.4 %) 0.390 107 (24.4 %) 98 (22.4 %) 0.496
Heavy calcification 26 (5.8 %) 28 (10.9 %) 0.013 62 (14.0 %) 85 (19.4 %) 0.032
Lesion type B2/C 300 (66.7 %) 171 (67.6 %) 0.803 245 (55.4 %) 241 (55.0 %) 0.903
Visible thrombus 383 (84.5 %) 223 (87.1 %) 0.352 49 (11.1 %) 39 (8.9 %) 0.276
Thrombosuction 250 (54.9 %) 142 (55.3 %) 0.937 11 (2.5 %) 6 (1.4 %) 0.222
Total stent length (mm) 25.3±14.7 27.7±16.5 0.046 28.2 ±18.9 28.2 ±16.0 0.986
Max stent diameter (mm) 3.1±0.4 3.1±0.3 0.676 3.1±0.6 3.1±0.5 0.436
No. of stents/patients 1.4±0.7 1.4±0.7 0.396 1.5±0.7 1.5±0.8 0.475
Glycoprotein IIb/IIIa inhibitor treatment 346 (76.0 %) 196 (76.3 %) 0.947 98 (22.3 %) 82 (18.7 %) 0.181
Postprocedural TIMI flow grade 3 431 (94.9 %) 238 (92.6 %) 0.206 428 (98.2 %) 420 (97.0 %) 0.262
Data are expressed as number (percentage) or as mean±SD
TIMI thrombolysis in myocardial infarction
Table 3 Clinical endpoints at 2 years
STEMI Other indications
Variable EES (N=450) SES (N=257) p value EES (N=436) SES (N=432) p value
Primary composite endpointa 27 (6.0) 24 (9.3) 0.099 51 (11.7) 46 (10.6) 0.624
Mortality
- All-cause 15 (3.3) 14 (5.4) 0.173 25 (5.7) 19 (4.4) 0.370
- Cardiac 10 (2.2) 8 (3.1) 0.470 16 (3.7) 10 (2.3) 0.242
Myocardial infarction 6 (1.3) 5 (1.9) 0.527 6 (1.4) 8 (1.9) 0.578
Target vessel revascularisation 15 (3.3) 13 (5.1) 0.258 33 (7.6) 32 (7.4) 0.928
Target lesion revascularisation 7 (1.6) 3 (1.2) 0.674 19 (4.4) 17 (3.9) 0.755
Stent thrombosis
- Definite 3 (0.7) 0 (0.0) 0.190 3 (0.7) 4 (0.9) 0.695
- Definite/probable 6 (1.3) 7 (2.7) 0.186 4 (0.9) 5 (1.2) 0.727
- Early 3 (0.7) 6 (2.3) 0.057 1 (0.2) 2 (0.5) 0.558
- Late 2 (0.4) 1 (0.4) 0.913 0 (0.0) 1 (0.2) 0.315
- Very late 1 (0.2) 0 (0.0) 0.449 3 (0.7) 2 (0.5) 0.661
Values are expressed as number (percentage)
a Cardiac mortality, myocardial infarction and target vessel revascularisation
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individual components of the composite endpoint, target le-
sion revascularisation (TLR) and definite or probable ST. TLR
was defined as any repeat intervention or bypass grafting of
the target lesion previously treated with stenting along with
the 5 mm proximal or distal vessel. ST was defined in accor-
dance with the Academic Research Consortium definitions
[13].
Statistical analyses
Comparisons were made according to randomised treatment
and presentation with or without STEMI. Continuous vari-
ables are presented as means with standard deviations or
medians with interquartile range (IQR) and were compared
using Student’s t-test. Categorical variables are expressed as
counts and percentages and were compared by means of
Pearson’s χ2 test. All statistical tests were 2-tailed and a
p-value <0.05 was considered statistically significant. Time-
to-event analyses were performed using Kaplan-Meier curves,
which were compared using log-rank tests. To adjust for
unbalanced baseline characteristics, Cox proportional hazards
analyses were performed. The proportional hazards assump-
tion was investigated visually. Adjusted effect sizes were
calculated for primary and secondary endpoints with a
p-value less than 0.10 as judged by log rank test.
Adjustment was performed for characteristics significantly
differing between groups (p<0.05), which were incorporated
in the multivariable models. Analyses were repeated with a
variable stating the trial the patient originated from, to evalu-
ate the influence of individual trials on the results.
To avoid dropping of events due to missing baseline
information, multiple imputation was performed for the
baseline variables that were included in the multivariable
models: presence of heavy calcification was unknown in
four patients (three EES and one SES) and total stent length
was unknown in four patients (three EES and one SES).
Reasons for missing data were unknown and assumed to be
random. Total stent length was log transformed to meet the
assumption for normal distribution. Missing data values
were imputed for heavy calcification and total stent length
using the following predictors: age, gender, cardiac risk
factors, cardiac history, renal insufficiency, indication for
PCI, target lesion, lesion type, number of vessel disease,
heavy calcification, total stent length, max stent diameter,
and number of stents per patient. Twenty imputed datasets
were created and Cox proportional hazards analyses were
performed on the pooled datasets [14]. Analyses were per-
formed using IBM SPSS version 21.
Results
In total, 1602 patients were randomised in the XAMI and
APPENDIX-AMI trials, of which 902 to EES and 700 to
SES. Two-year follow-up data were available for 1575 pa-
tients (98.3 %). The presenting diagnosis was stable angina in
Fig. 1 Two-year primary outcome according to randomised stent in
STEMI patients
Fig. 2 Definite/probable stent
thrombosis with landmark
analysis at 30-days in STEMI
population
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526 patients (32.8 %), unstable angina or non-STEMI in 364
patients (22.7 %) and STEMI in 712 patients (44.4 %). After
pooling of the two trials, the primary endpoint occurred in
8.8 % of EES patients vs. 10.2 % of SES patients during 2-
year follow-up in the overall population, HR 0.86 (95 % CI
0.62–1.18), p=0.347. Secondary endpoints were also bal-
anced between the groups.
Stratification on presenting diagnosis
STEMI patients were younger than patients without STEMI
and more likely to smoke but had lower rates of comorbidity
and other risk factors (Table 1). Coronary thrombus was more
common in STEMI, but rates of heavy calcification, bifurca-
tions and multivessel disease were lower. Stent length and
number of stents used were also lower in STEMI, but stent
diameter was slightly larger. Finally, glycoprotein IIb/IIIa
inhibitor use was more common in STEMI while TIMI 3 flow
after procedure was less often achieved. During 2-year follow-
up, STEMI patients showed lower rates of the primary end-
point (7.2 % vs. 11.2 %, p=0.007) and TLR (1.4 % vs. 4.1 %,
p=0.001) compared with patients without STEMI.
In the STEMI population, EES showed less calcified le-
sions and total stent length was shorter compared with SES
(Table 2). During 2-year follow-up, randomisation to EES
resulted in a similar primary endpoint rate (unadjusted HR
0.63, 95 % CI 0.36–1.09, p=0.097, adjusted HR 0.66, 95 %
CI 0.38–1.15, p=0.141) compared with SES (Table 3, Fig. 1).
A trend was observed for reduced early definite/probable ST
in EES. However, long-term ST rates were low and similar
(Fig. 2). At 1-year, aspirin (or coumadin) compliance was
94.8 % in EES versus 91.5 % in SES (p= 0.092).
Thienopyridine compliance was 95.6 % in EES versus
91.8 % in SES (p=0.040). Two patients were not on dual
antiplatelet therapy at the time of ST: 1 EES and 1 SES patient,
both suffering probable ST.
In the population without STEMI, EES patients showed
lower rates of hypertension, prior PCI, bypass grafting and
heavy calcification compared with SES patients (Tables 1
and 2). At 2 years, EES and SES showed similar rates of the
primary endpoint (HR 1.10, 95 % CI 0.74–1.64, p=0.637)
(Table 3, Fig. 3). Other secondary endpoints were also
balanced. Definite/probable ST rates were low and similar
between the groups (Fig. 4). Aspirin compliance during
1 year was 97.6 % in EES and 99.3 % in SES (p=0.047).
Thienopyridine compliance was 96.8 % in EES and 97.5 %
in SES (p=0.518).
The p-value for interaction between randomised stent and
presenting diagnosis (STEMI vs. other) was 0.104 (HR 1.76,
95 % CI 0.89–3.46) for the primary endpoint.
Discussion
The present pooled analysis of the randomised XAMI and
APPENDIX-AMI trials provided 2-year outcome data of EES
Fig. 3 Two-year primary outcome according to randomised stent in
patients without STEMI
Fig. 4 Definite/probable stent
thrombosis with landmark
analysis at 30-days in population
without STEMI
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and SES according to clinical presentation. The performance
of the first- and second-generation DES was found to be
similar and independent of clinical presentation. Importantly,
despite wide inclusion criteria and a large sub-population of
STEMI patients, both devices showed a comparable safety at
long-term follow-up.
Implantation of first-generation DES in the previously
off-label indication of acute MI was controversial until pub-
lication of the HORIZONS-AMI trial, which confirmed the
safety and efficacy of PES compared with BMS in primary
PCI [15]. Superiority of second-generation EES over PES in
acute coronary syndromes has been established but data
comparing EES with previous golden standard SES are less
abundant, especially in setting of STEMI [16]. In SORT
OUT IV, EES and SES showed comparable outcomes up
to 2 years, with the exception of a lower rate of definite ST
in EES patients [7]. However, only 10 % of patients pre-
sented with STEMI. The other major trials that compared
EES and SES showed no differences in outcome in up to
3 years of follow-up [8–10]. Also in these trials, the STEMI
population was strongly underrepresented, making
randomised data of EES and SES in STEMI patients scarce
beyond 1 year. In contrast, almost half the patients included
in the current study presented with STEMI.
In the STEMI population of the present study, event rates
were lower than in the population without STEMI, likely
explained by the generally less complex thrombotic lesions
in STEMI. Although EES appeared to perform slightly
better than SES, no significant differences in the primary
outcome measure were observed. Nonetheless, a strong
trend toward reduced early definite/probable ST hinted at a
possible advantage of EES over SES in the early phase after
MI. In contrast, clinical outcomes were balanced between
EES and SES in patients presenting with a diagnosis other
than STEMI, which is in accordance with previous trials
[8–10].
Findings observed in the STEMI population were compa-
rable with reports of the EXAMINATIONS trial, in which
EES use resulted in a lower rate of early definite/probable ST
compared with BMS in STEMI patients [17]. At 1-year, the
definite/probable ST rate was 0.9 % in the EES group, com-
parable with the 1.1 % rate observed in this study.
Additionally, Kalesan et al. performed a propensity matched
comparison of EES and SES in ACS patients and found a
reduction in both the primary endpoint and ST during 3-year
follow-up [18].
Important differences of EES compared with SES are
the thin strut design and the biocompatible polymer. In
ex-vivo and in-vivo models, thin struts were less
thrombogenic and the slim design of EES has been
associated with faster endothelialisation compared with
SES [19, 20]. Also, the biocompatible polymer of EES
may be assoc ia ted wi th a reduced long- te rm
inflammatory response. While the current study found
reassuringly low rates of ST in both DES, very long-
term monitoring is necessary to establish a potential
benefit of EES over SES. In the TYPHOON trial, SES
showed a late ‘catch-up’ phenomenon for ST, i.e. the
relatively low early ST rates were abolished by higher
very late ST rates compared with BMS in STEMI
patients during 4 years of follow-up [21].
Although the polymer applied in EES is more biocompat-
ible than the SES polymer coating, additional improvement
may be achieved with a biodegradable polymer coating. The
COMFORTABLE AMI trial compared biolimus-eluting
stents with BMS in STEMI patients but did not find a reduc-
tion in 1-year definite/probable ST [22]. However, long-term
follow-up will have to show if STEMI patients benefit from
DES with biodegradable polymer, as the main effect of a
biodegradable polymer in reducing ST becomes evident after
1 year [23].
Limitations
Our study is limited by its post hoc nature and therefore
findings should be considered hypothesis generating. XAMI
included only patients with acute MI, while APPENDIX-AMI
included all-comer patients. Furthermore, the randomisation
rate differed between XAMI (2:1) and APPENDIX-AMI (1:1)
which created baseline misbalance between the groups, al-
though multivariable corrections were performed to adjust for
these differences. Finally, the analysis was underpowered to
detect differences in the ST rates.
Conclusions
The present pooled analysis of the XAMI and APPENDIX-
AMI trials found similar outcomes between EES and SES
during 2 years of follow-up, regardless of clinical presentation.
Long-term ST rates were reassuringly low in both stent types.
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